PrimeVigilance, one of the world’s leading pharmacovigilance and medical information services providers is pleased to announce that Dr. Joerg Seebeck, Chief Medical Officer and Mr. Andy Harbrow, Global.

 

Guildford, UK – 16 March 2015. PrimeVigilance, one of the world’s leading pharmacovigilance and medical information services providers is pleased to announce that Dr. Joerg Seebeck, Chief Medical Officer and Mr. Andy Harbrow, Global Medical Services Manager of PrimeVigilance, have been invited to speak at the DIA USA 2015 51st Annual Meeting taking place from 14th to 18th June, 2015. The event will be held at the Walter E. Washington Convention Center in Washington, DC.

Now in its 51st year, the DIA USA Annual Meeting is one of the largest multidisciplinary events that bring together Life Sciences professionals across all disciplines, with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies for patients.

Dr Joerg Seebeck will join the Clinical Safety and Pharmacovigilance Symposium panel on Wednesday 17th June at 10:30 am on the “Risk of Drug-Induced QT Interval Prolongation by Monoclonal Antibody Medicines: A Review of Data from an EU Database.”

Mr Andy Harbrow will join the Validation Symposium panel on Wednesday 17th June at 1:30 pm on the “Establishment of a new Medical Information Database: To Validate or Not to Validate – That Is the Question.”

Neil Clark, Director of PrimeVigilance said: “PrimeVigilance is committed to patient safety services and is at the forefront of developments in the Pharmacovigilance and Medical Information industry providing quality services and consultancy to our international clients. We are pleased that Dr Joerg Seebeck and Mr. Andy Harbrow have been invited to speak at one of the largest and prestigious events in the sector.”

-END- 

For further information, please contact:

Florence Denance Habek, Marketing and Business Development Manager

Tel: + 385 14628 503

E-mail: florence.denance.habek@primevigilance.com

About PrimeVigilance

The pharmacovigilance  services offered by PrimeVigilance support essential regulatory and scientific elements  required to obtain and maintain a product license within Europe. This includesQualified Persons,  a compliant PV System with robust Quality Management, consistent Adverse Event data capture, expedited reporting, literature screening, preparation of Periodic Safety Update Reports, signal detection and evaluation, benefit-risk assessment, Risk Management Planning, compliance auditing, support during crisis and ad hoc consulting assignments. PrimeVigilance also offers a multi-language Medical Information service. PrimeVigilance has grown organically since 2008 and now has approximately 140 staff employed in its main offices in Guildford UK, and Zagreb, Croatia, as well as an international network of consultants. PrimeVigilance is currently providing services across more than 100 countries.

For more information, visit: www.primevigilance.com

Share this:

 


NEXT NEWS:

PREVIOUS NEWS:

This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Cookie Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

  • __cfduid

Decline all Services
Accept all Services